D Orazio & Associates Inc. lifted its holdings in CVS Health Co. (NYSE:CVS) by 46.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 638 shares of the pharmacy operator’s stock after purchasing an additional 203 shares during the period. D Orazio & Associates Inc.’s holdings in CVS Health were worth $54,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of CVS. Capital International Investors lifted its stake in shares of CVS Health by 55.8% in the 2nd quarter. Capital International Investors now owns 27,400,512 shares of the pharmacy operator’s stock worth $2,286,301,000 after purchasing an additional 9,809,050 shares during the period. Nordea Investment Management AB lifted its stake in shares of CVS Health by 89.6% in the 3rd quarter. Nordea Investment Management AB now owns 17,420,988 shares of the pharmacy operator’s stock worth $1,519,284,000 after purchasing an additional 8,235,096 shares during the period. Hotchkis & Wiley Capital Management LLC bought a new position in shares of CVS Health in the 2nd quarter worth approximately $291,690,000. Veritas Asset Management LLP increased its holdings in CVS Health by 36.4% in the 3rd quarter. Veritas Asset Management LLP now owns 11,153,024 shares of the pharmacy operator’s stock worth $946,446,000 after acquiring an additional 2,975,111 shares in the last quarter. Finally, Amundi purchased a new stake in CVS Health in the 2nd quarter worth approximately $201,455,000. Hedge funds and other institutional investors own 75.84% of the company’s stock.
Several research firms recently issued reports on CVS. Credit Suisse Group increased their target price on shares of CVS Health from $107.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, December 10th. Tigress Financial increased their target price on shares of CVS Health from $108.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, December 23rd. Seaport Global Securities began coverage on shares of CVS Health in a report on Wednesday, December 1st. They issued a “buy” rating and a $110.00 target price for the company. Truist Securities increased their target price on shares of CVS Health from $118.00 to $124.00 and gave the stock a “buy” rating in a report on Wednesday, January 5th. Finally, Cowen increased their price objective on shares of CVS Health from $103.00 to $114.00 and gave the company an “outperform” rating in a report on Friday, December 10th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $112.04.
CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 3rd. The pharmacy operator reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.18. The company had revenue of $73.79 billion during the quarter, compared to the consensus estimate of $70.52 billion. CVS Health had a return on equity of 14.16% and a net margin of 2.66%. CVS Health’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the company earned $1.66 earnings per share. As a group, equities research analysts expect that CVS Health Co. will post 8.36 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 1st. Investors of record on Friday, January 21st will be given a $0.55 dividend. The ex-dividend date is Thursday, January 20th. This is an increase from CVS Health’s previous quarterly dividend of $0.50. This represents a $2.20 dividend on an annualized basis and a yield of 2.09%. CVS Health’s dividend payout ratio (DPR) is currently 34.97%.
In other news, COO Jonathan C. Roberts sold 108,870 shares of CVS Health stock in a transaction on Wednesday, November 3rd. The stock was sold at an average price of $95.00, for a total transaction of $10,342,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Troyen A. Brennan sold 28,159 shares of CVS Health stock in a transaction on Monday, November 1st. The stock was sold at an average price of $90.00, for a total value of $2,534,310.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 219,786 shares of company stock valued at $20,159,576. Corporate insiders own 0.69% of the company’s stock.
CVS Health Company Profile
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate/Other. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
Featured Article: What is a stock buyback?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.